A Case of Dasatinib-Induced Keratosis Pilaris

Olivia Arriaza; Frank Winsett; Janice Wilson; Brent Kelly

doi:10.25251/skin.7.1.13

A Case of Dasatinib-Induced Keratosis Pilaris

Dermatology

Research output: Contribution to journal › Article › peer-review

Abstract

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) indicated for treatment of chronic myeloid leukemia (CML). Dasatinib targets several proteins specific to cancer pathogenesis such as Bcr-Abl, Src, c-kit and PDGFRb. Cutaneous reactions are a well-documented side effect of many TKIs, however, there are limited reports and characterization of dasatinib induced rash. We report a case of keratosis pilaris and follicular epithelial thinning in a 19-year-old patient one month after beginning dasatinib for treatment of CML. This report suggests a possible role of dasatinib in the induction of epithelial follicular instability via reduced Src activity and subsequent down regulation of EGFR.

Original language	English (US)
Pages (from-to)	625-630
Number of pages	6
Journal	SKIN: Journal of Cutaneous Medicine
Volume	7
Issue number	1
DOIs	https://doi.org/10.25251/skin.7.1.13
State	Published - Jan 10 2023

ASJC Scopus subject areas

Dermatology

Access to Document

10.25251/skin.7.1.13

Cite this

@article{5afea92bcb224bbebed79458911794fb,

title = "A Case of Dasatinib-Induced Keratosis Pilaris",

abstract = "Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) indicated for treatment of chronic myeloid leukemia (CML). Dasatinib targets several proteins specific to cancer pathogenesis such as Bcr-Abl, Src, c-kit and PDGFRb. Cutaneous reactions are a well-documented side effect of many TKIs, however, there are limited reports and characterization of dasatinib induced rash. We report a case of keratosis pilaris and follicular epithelial thinning in a 19-year-old patient one month after beginning dasatinib for treatment of CML. This report suggests a possible role of dasatinib in the induction of epithelial follicular instability via reduced Src activity and subsequent down regulation of EGFR.",

author = "Olivia Arriaza and Frank Winsett and Janice Wilson and Brent Kelly",

note = "Publisher Copyright: {\textcopyright} 2022 THE AUTHORS.",

year = "2023",

month = jan,

day = "10",

doi = "10.25251/skin.7.1.13",

language = "English (US)",

volume = "7",

pages = "625--630",

journal = "SKIN: Journal of Cutaneous Medicine",

issn = "2574-1624",

publisher = "National Society for Cutaneous Medicine",

number = "1",

}

TY - JOUR

T1 - A Case of Dasatinib-Induced Keratosis Pilaris

AU - Arriaza, Olivia

AU - Winsett, Frank

AU - Wilson, Janice

AU - Kelly, Brent

PY - 2023/1/10

Y1 - 2023/1/10

N2 - Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) indicated for treatment of chronic myeloid leukemia (CML). Dasatinib targets several proteins specific to cancer pathogenesis such as Bcr-Abl, Src, c-kit and PDGFRb. Cutaneous reactions are a well-documented side effect of many TKIs, however, there are limited reports and characterization of dasatinib induced rash. We report a case of keratosis pilaris and follicular epithelial thinning in a 19-year-old patient one month after beginning dasatinib for treatment of CML. This report suggests a possible role of dasatinib in the induction of epithelial follicular instability via reduced Src activity and subsequent down regulation of EGFR.

AB - Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) indicated for treatment of chronic myeloid leukemia (CML). Dasatinib targets several proteins specific to cancer pathogenesis such as Bcr-Abl, Src, c-kit and PDGFRb. Cutaneous reactions are a well-documented side effect of many TKIs, however, there are limited reports and characterization of dasatinib induced rash. We report a case of keratosis pilaris and follicular epithelial thinning in a 19-year-old patient one month after beginning dasatinib for treatment of CML. This report suggests a possible role of dasatinib in the induction of epithelial follicular instability via reduced Src activity and subsequent down regulation of EGFR.

UR - https://www.scopus.com/pages/publications/85146266011

UR - https://www.scopus.com/pages/publications/85146266011#tab=citedBy

U2 - 10.25251/skin.7.1.13

DO - 10.25251/skin.7.1.13

M3 - Article

AN - SCOPUS:85146266011

SN - 2574-1624

VL - 7

SP - 625

EP - 630

JO - SKIN: Journal of Cutaneous Medicine

JF - SKIN: Journal of Cutaneous Medicine

IS - 1

ER -

A Case of Dasatinib-Induced Keratosis Pilaris

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this